Hypoxic radiosensitization: Adored and ignored

Journal of Clinical Oncology

Volumn 25, Issue 26, 2007, Pages 4066-4074

  Overgaard, Jens ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; CARBONATE DEHYDRATASE IX; FLUOROAZOMYCINARABINOFURANOSIDE F 18; HYPOXIA INDUCIBLE FACTOR 1ALPHA; TIRAPAZAMINE; UNCLASSIFIED DRUG; RADIOSENSITIZING AGENT;

CANCER RADIOTHERAPY; EVIDENCE BASED MEDICINE; HUMAN; HYPERBARIC OXYGEN; HYPOXIA; IMMUNOHISTOCHEMISTRY; IONIZING RADIATION; METASTASIS; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOCHEMISTRY; RADIOSENSITIVITY; RADIOSENSITIZATION; REOXYGENATION; REVIEW; CELL HYPOXIA; MULTIMODALITY CANCER THERAPY; NEOPLASM; PATHOPHYSIOLOGY;

CELL HYPOXIA; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS; RADIATION-SENSITIZING AGENTS;

EID: 34748860952     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.7878     Document Type: Review

References (74)

1. Schwarz G: Ueber Desensibilisierung gegen röntgen- und radiumstrahlen. Munchener Medizinische Wochenschrift 24:1-2, 1909
2. Schwarz G: Merkwürdige Schwankungen der röntgenempfindlichkeit bein einem und demselben patienten. Wien Med Wochenschr 64:2597-2598, 1914
3. Nordsmark M, Overgaard M, Overgaard J: Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41:31-39, 1996
4. Vaupel P: Oxygenation of human tumors. Strahlenther Onkol 166:377-386, 1990
5. Overgaard J, Horsman MR: Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 6:10-21, 1996
6. Chan DA, Giaccia AJ: Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev [epub ahead of print on April 26, 2007]
7. Harris AL: Hypoxia: A key regulatory factor in tumour growth. Nat Rev Cancer 2:38-47, 2002
8. Overgaard J: Sensitization of hypoxic tumor cells: Clinical experience. Int J Radiat Biol 56:801-811, 1989
9. Brown JM, Wilson WR: Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4:437-447, 2004
10. Moeller BJ, Richardson RA, Dewhirst MW: Hypoxia and radiotherapy: Opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev [epub ahead of print on April 14, 2007]
11. Gray LH, Conger AD, Ebert M, et al: The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26:638-648, 1953
12. Churchill-Davidson I: The oxygen effect in radiotherapy: Historical review. Front Radiat Ther Oncol 1:1-15, 1968
13. Rischin D, Peters L, Fisher R, et al: Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 23:79-87, 2005
14. Rischin D, Hicks RJ, Fisher R, et al: Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 24:2098-2104, 2006
15. Thomlinson RH, Gray LH: The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9:539-549, 1955
16. Nordsmark M, Bentzen SM, Rudat V, et al: Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy: An international multi-center study. Radiother Oncol 77:18-24, 2005
17. Tatum JL, Kelloff GJ, Gillies RJ, et al: Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 82:699-757, 2006
18. Nordsmark M, Eriksen JG, Gebski V, et al: Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiother Oncol 83:389-397, 2007
19. Nordsmark M, Loncaster J, Aquino-Parsons C, et al: The prognostic value of pimonidazole and tumour po2 in human cervix carcinomas after radiation therapy: A prospective international multicenter study. Radiother Oncol 80:123-131, 2006
20. Bentzen L, Keiding S, Nordsmark M, et al: Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. Radiother Oncol 67:339-344, 2003
21. Vaupel P, Mayer A: Hypoxia in cancer: Significance and impact on clinical outcome. Cancer Metastasis Rev [epub ahead of print on April 18, 2007]
22. Kaanders JH, Wijffels KI, Marres HA, et al: Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 62:7066-7074, 2002
23. Koukourakis MI, Bentzen SM, Giatromanolaki A, et al: Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24:727-735, 2006
24. Erler JT, Bennewith KL, Nicolau M, et al: Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440:1222-1226, 2006
25. Newbold K, Partridge M, Cook G, et al: Advanced imaging applied to radiotherapy planning in head and neck cancer: A clinical review. Br J Radiol 79:554-561, 2006
26. Grau C, Overgaard J: The influence of radiation dose on the magnitude and kinetics of reoxygenation in a C3H mammary carcinoma. Radiat Res 122:309-315, 1990
27. Eschmann SM, Paulsen F, Bedeshem C, et al: Hypoxia-imaging with (18)F-misonidazole and PET: Changes of kinetics during radiotherapy of head-and-neck cancer. Radiother Oncol 83:406-410, 2007
28. Thorwarth D, Eschmann SM, Paulsen F, et al: A model of reoxygenation dynamics of head-and-neck tumors based on serial 18F-fluoromisonidazole positron emission tomography investigations. Int J Radiat Oncol Biol Phys 68:515-521, 2007
29. Adams GE: Hypoxic cell sensitizers for radiotherapy, in: Cancer (ed 6). New York, NY, F.F. Becker Plenum Press, 1977
30. Dische S: Chemical sensitizers for hypoxic cells: A decade of experience in clinical radiotherapy. Radiother Oncol 3:97-115, 1985
31. Overgaard J: Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res 6:507-516, 1994
32. Saunders M, Dische S: Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide. Br J Cancer 27:S271-S278, 1996 (suppl)
33. Kaanders JH, Bussink J, van der Kogel AJ: Clinical studies of hypoxia modification in radiotherapy. Semin Radiat Oncol 14:233-240, 2004
34. Horsman MR, Siemann DW: Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 66:11520-11539, 2006
35. Wardman P: Chemical radiosensitizers for use in radiotherapy. Clin Oncol (R Coll Radiol) 19:397-417, 2007
36. Horsman MR: Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours: A review. Acta Oncol 34:571-587, 1995
37. Watson ER, Halnan KE, Dische S, et al: Hyperbaric oxygen and radiotherapy: A Medical Research Council trial in carcinoma of the cervix. Br J Radiol 51:879-887, 1978
38. Kaanders JH, Bussink J, van der Kogel AJ: ARCON: A novel biology-based approach in radiotherapy. Lancet Oncol 3:728-737, 2002
39. Overgaard J, Hansen HS, Overgaard M, et al: A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma: Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 46:135-146, 1998
40. Bennett M, Feldmeier J, Smee R, et al: Hyperbaric oxygenation for tumour sensitisation to radiotherapy. Cochrane Database Syst Rev 4:CD005007, 2005
41. Huncharek M: Meta-analytic re-evaluation of misonidazole in the treatment of high grade astrocytoma. Anticancer Res 18:1935-1939, 1998
42. Dayes IS, Abuzallouf S: Local tumour control in women with carcinoma of the cervix treated with the addition of nitroimidazole agents to radiotherapy: A meta-analysis. Br J Radiol 78:777-782, 2005
43. Fu KK, Cooper JS, Marcial VA, et al: Evolution of the Radiation Therapy Oncology Group clinical trials for head and neck cancer. Int J Radiat Oncol Biol Phys 35:425-438, 1996
44. Machin D, Stenning SP, Parmar MK, et al: Thirty years of Medical Research Council randomized trials in solid tumours. Clin Oncol (R Coll Radiol) 9:100-114, 1997
45. Hoskin PJ, Saunders MI, Dische S: Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: Hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide. Cancer 86:1322-1328, 1999
46. Sundfør K, Trope C, Suo Z, et al: Normobaric oxygen treatment during radiotherapy for carcinoma of the uterine cervix: Results from a prospective controlled randomized trial. Radiother Oncol 50:157-165, 1999
47. Dische S, Saunders MI, Sealy R, et al: Carcinoma of the cervix and the use of hyperbaric oxygen with radiotherapy: A report of a randomised controlled trial. Radiother Oncol 53:93-98, 1999
48. Glassbum JR, Brady LW, Plenk HP: Hyperbaric oxygen in radiation therapy. Cancer 39:751-765, 1977 (suppl 2)
49. Chan P, Milosevic M, Fyles A, et al: A phase III randomized study of misonidazole plus radiation vs. radiation alone for cervix cancer. Radiother Oncol 70:295-299, 2004
50. Dobrowsky W, Huigol NG, Jayatilake RS, et al: AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: Results of an IAEA multicentre randomised trial. Radiother Oncol 82:24-29, 2007
51. Galecki J, Dukowicz A, Hliniak A, et al: Comparison of the effectiveness of different methods of irradiation using metronidazole as a radiation-sensitizing agent in patients with laryngeal cancer: Controlled clinical studies. Nowotwory 39:111-115, 1989
52. Ullal SD, Shenoy KK, Pai MR, et al: Safety and radiosensitizing efficacy of sanazole (AK 2123) in oropharyngeal cancers: Randomized controlled double blind clinical trial. Indian J Cancer 43:151-155, 2006
53. Okkan S, Atkovar G, Sahinler I, et al: A randomised study of ornidazole as a radiosensitiser in carcinoma of the cervix: Long term results. Br J Cancer 27:S282-S286, 1996 (suppl)
54. Schwade JG, Kinsella TJ, Kelly B, et al: Clinical experience with intravenous misonidazole for carcinoma of the esophagus: Results in attempting radiosensitization of each fraction of exposure. Cancer Invest 2:91-95, 1984
55. Sunamura M, Karasawa K, Okamoto A, et al: Phase III trial of radiosensitizer PR-350 combined with intraoperative radiotherapy for the treatment of locally advanced pancreatic cancer. Pancreas 28:330-334, 2004
56. Eschwege F, Sancho-Garnier H, Chassagne D, et al: Results of a European randomized trial of Etanidazole combined with radiotherapy in head and neck carcinomas. Int J Radiat Oncol Biol Phys 39:275-281, 1997
57. Huilgol NG, Chatterjee N, Mehta AR: An overview of the initial experience with AK-2123 as a hypoxic cell sensitizer with radiation in the treatment of advanced head and neck cancers. Int J Radiat Oncol Biol Phys 34:1121-1124, 1996
58. Rubin P, Hanley J, Keys HM, et al: Carbogen breathing during radiation therapy: The Radiation Therapy Oncology Group Study. Int J Radiat Oncol Biol Phys 5:1963-1970, 1979
59. Evans JC, Sanfilippo LJ: Oxygen tension of oral cavity carcinoma. Radiol Clin Biol 39:54-58, 1970
60. Evans JC, Cavanaugh PJ: Clinical trial of atmospheric oxygen breathing during radiotherapy for cancer of the oropharynx. Radiol Clin (Basel) 44:210-213, 1975
61. Mendenhall WM, Morris CG, Amdur RJ, et al: Radiotherapy alone or combined with carbogen breathing for squamous cell carcinoma of the head and neck: A prospective, randomized trial. Cancer 104:332-337, 2005
62. Senapati SN, Samanta DR, Giri SK, et al: AK-2123 as a radiosensitizer in stage IIIB carcinoma Cervix. Radiother Oncol 43:S165, 1997 (suppl 2, abstr)
63. Senapati SN, Samanta DR, Giri SK, et al: AK-2123 as a radiosensitizer in stage IIIB carcinoma cervix. Sensitization Newsletter 4:1-3, 1997
64. Okkan S, Uzel R, Yazici A, et al: Effect of ornisazole on fractionated irradiation in carcinoma of the cervix and larynx, in: Radiotherapy in Developing Countries. Proceedings Series. Vienna, Austria, International Atomic Energy Agency, 1987, pp 271-280
65. Okkan S, Uzel R, Ober A, et al: A randomized study of ornidazole as a radiosensitizer in high-grade astrocytomas: Preliminary report. Radiosensitization Newsletter 7:1-3, 1988
66. Okkan S, Yazici Z, Uzel R, et al: Use of ornidazole in fractionated radiotherapy: Dose tolerance, serum and tumour tissue concentration. Radiother Oncol 5:295-301, 1986
67. Lyman GH, Kuderer NM: The strengths and limitations of meta-analyses based on aggregate data. BMC Med Res Methodol 5:14, 2005
68. Parmar MK, Torri V, Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815-2834, 1998
69. Duchateau L, Pignon JP, Bijnens L, et al: Individual patient-versus literature-based meta-analysis of survival data: Time to event and event rate at a particular time can make a difference, an example based on head and neck cancer. Control Clin Trials 22:538-547, 2001
70. Urtasun RC, Band PR, Chapman JD, et al: Radiation plus metronidazole for glioblastoma. N Engl J Med 296:757, 1977
71. Overgaard J, Eriksen JG, Nordsmark M, et al: Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: Results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6:757-764, 2005
72. Jonathan RA, Wijffels KI, Peeters W, et al: The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother Oncol 79:288-297, 2006
73. Eriksen JG, Overgaard J: Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: An evaluation of the DAHANCA 5 study. Radiother Oncol 83:383-388, 2007
74. Gray LH: Radiobiologic basis of oxygen as a modifying factor in radiation therapy. Am J Roentgenol Radium Ther Nucl Med 85:803-815, 1961